Search Results - "Dauki, Anees M"

Approaches to handling missing or “problematic” pharmacology data: Pharmacokinetics by Irby, Donald J., Ibrahim, Mustafa E., Dauki, Anees M., Badawi, Mohamed A., Illamola, Sílvia M., Chen, Mingqing, Wang, Yuhuan, Liu, Xiaoxi, Phelps, Mitch A., Mould, Diane R.

“…Missing or erroneous information is a common problem in the analysis of pharmacokinetic (PK) data. This may present as missing or inaccurate dose level or dose…”
Get full text

Pharmacokinetics, pharmacodynamics, and safety of GS‐3583, a FLT3 agonist Fc fusion protein, from single‐ascending‐dose phase I study in healthy participants by Dauki, Anees M., Rajakumaraswamy, Nishanthan, Trowe, Torsten, Weng, Winnie, Lin, Kai‐Wen, Elboudjwarej, Emon, Qin, Ann Ran‐Ran, Schwabe, Christian, Kuhne, Michelle R., Othman, Ahmed A.

“…Conventional dendritic cells subtype 1 (cDC1) play a vital role in the priming and expansion of tumor‐specific CD8+ T cells and their recruitment to tumor…”
Get full text

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor by Liva, Sophia G, Tseng, Yu‐Chou, Dauki, Anees M, Sovic, Michael G, Vu, Trang, Henderson, Sally E, Kuo, Yi‐Chiu, Benedict, Jason A, Zhang, Xiaoli, Remaily, Bryan C, Kulp, Samuel K, Campbell, Moray, Bekaii‐Saab, Tanios, Phelps, Mitchell A, Chen, Ching‐Shih, Coss, Christopher C

“…No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic…”
Get full text

GATM Polymorphism Associated with the Risk for Statin-Induced Myopathy Does Not Replicate in Case-Control Analysis of 715 Dyslipidemic Individuals by Luzum, Jasmine A., Kitzmiller, Joseph P., Isackson, Paul J., Ma, Changxing, Medina, Marisa W., Dauki, Anees M., Mikulik, Eduard B., Ochs-Balcom, Heather M., Vladutiu, Georgirene D.

“…Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. A polymorphism affecting the gene encoding glycine…”
Get full text

Oral Glucose Tolerance Test: An Informative Endpoint or an Added Burden in Metformin Drug–Drug Interaction Studies? by Dauki, Anees M., Hsueh, Chia‐Hsiang, Cherala, Ganesh, Othman, Ahmed A.

Get full text

Phase I Study of GS-3583, an FMS-like Tyrosine Kinase 3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors by Tolcher, Anthony W., Brody, Joshua D., Rajakumaraswamy, Nishanthan, Kuhne, Michelle, Trowe, Torsten, Dauki, Anees M., Pai, Shantheri, Han, Ling, Lin, Kai-Wen, Petrarca, Michael, Kummar, Shivaani

“…Abstract Purpose: GS-3583, an FMS-like tyrosine kinase 3 (FLT3) agonist Fc fusion protein, expanded conventional dendritic cells (cDC) in the periphery of…”
Get full text

Transcriptionally Active Androgen Receptor Splice Variants Promote Hepatocellular Carcinoma Progression by Dauki, Anees M, Blachly, James S, Kautto, Esko A, Ezzat, Sameera, Abdel-Rahman, Mohamed H, Coss, Christopher C

“…Owing to the marked sexual dimorphism of hepatocellular carcinoma (HCC), sex hormone receptor signaling has been implicated in numerous aspects of liver cancer…”
Get full text

Pharmacogenomics of statins: understanding susceptibility to adverse effects by Kitzmiller, Joseph P, Mikulik, Eduard B, Dauki, Anees M, Murkherjee, Chandrama, Luzum, Jasmine A

“…Statins are a cornerstone of the pharmacologic treatment and prevention of atherosclerotic cardiovascular disease. Atherosclerotic disease is a predominant…”
Get full text

Phase I Study of GS-3583, a FLT3 Agonist Fc Fusion Protein, in Patients with Advanced Solid Tumors by Tolcher, Anthony W, Brody, Joshua D, Rajakumaraswamy, Nishanthan, Kuhne, Michelle, Trowe, Torsten, Dauki, Anees M, Kochikar Pai, Shantheri, Han, Ling, Lin, Kai-Wen, Petrarca, Michael, Kummar, Shivaani

“…GS-3583, a FMS-like tyrosine kinase 3 (FLT3) agonist Fc fusion protein, expanded conventional dendritic cells (cDCs) in the periphery of healthy volunteers,…”
Get full text

Targeting Androgen Receptor Signaling in Hepatocellular Carcinoma by Dauki, Anees M

“…Hepatocellular carcinoma (HCC) is the second most common cause of cancer-related death in males worldwide. Globally, approximately 80% of HCC cases are caused…”
Get full text

GATM polymorphism associated with the risk for statin-induced myopathy not replicated in case-control analysis of 715 dyslipidemic individuals by Luzum, Jasmine A., Kitzmiller, Joseph P., Isackson, Paul J., Ma, Changxing, Medina, Marisa W., Dauki, Anees M., Mikulik, Eduard B., Ochs-Balcom, Heather M., Vladutiu, Georgirene D.

“…Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. A polymorphism affecting the gene encoding glycine…”
Get full text